Drug combination for newly diagnosed primary cns lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs — high-dose methotrexate, thiotepa, and zanubrutinib — for people newly diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with primary central nervous system lymphoma (PCNSL) — a lymphoma that starts in the brain or spinal cord.
- You are able to take care of yourself (ECOG score 0–2) and have a life expectancy of more than 3 months.
- You have at least one tumor that can be seen on an MRI or CT scan.
- Your blood counts, liver, kidney, and other organ functions meet the study's safety limits.
- You can have MRI or CT scans and spinal taps, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of two oral medications (zanubrutinib and lenalidomide) for older adults with a certain type of brain lymphoma. The goal is to see if this treatment can help control the disease with manageable side effects.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
Hear when a new Primary Central Nervous System Lymphoma (PCNSL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.